These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

811 related articles for article (PubMed ID: 18163003)

  • 61. Predicting vision gains with anti-VEGF therapy in neovascular age-related macular degeneration patients by using low-luminance vision.
    Frenkel RE; Shapiro H; Stoilov I
    Br J Ophthalmol; 2016 Aug; 100(8):1052-7. PubMed ID: 26541435
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Introduction: Understanding the role of angiogenesis and antiangiogenic agents in age-related macular degeneration.
    Bressler SB
    Ophthalmology; 2009 Oct; 116(10 Suppl):S1-7. PubMed ID: 19800534
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Bevacizumab and neovascular age related macular degeneration: pathogenesis and treatment.
    El-Mollayess GM; Noureddine BN; Bashshur ZF
    Semin Ophthalmol; 2011 May; 26(3):69-76. PubMed ID: 21609219
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Driving ability reported by neovascular age-related macular degeneration patients after treatment with ranibizumab.
    Bressler NM; Chang TS; Varma R; Suñer I; Lee P; Dolan CM; Ward J; Ianchulev T; Fine J
    Ophthalmology; 2013 Jan; 120(1):160-8. PubMed ID: 23009891
    [TBL] [Abstract][Full Text] [Related]  

  • 65. FGF21 Administration Suppresses Retinal and Choroidal Neovascularization in Mice.
    Fu Z; Gong Y; Liegl R; Wang Z; Liu CH; Meng SS; Burnim SB; Saba NJ; Fredrick TW; Morss PC; Hellstrom A; Talukdar S; Smith LE
    Cell Rep; 2017 Feb; 18(7):1606-1613. PubMed ID: 28199833
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Therapeutic Monoclonal Antibodies and Fragments: Bevacizumab.
    Klein A; Loewenstein A
    Dev Ophthalmol; 2016; 55():232-45. PubMed ID: 26502311
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [The role of laser photocoagulation in the anti-vascular endothelial growth factor therapy era].
    Wang F; Zhang P; Sun X
    Zhonghua Yan Ke Za Zhi; 2015 Dec; 51(12):885-7. PubMed ID: 26888269
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Ranibizumab in neovascular age-related macular degeneration.
    Kenneth TE; Kertes PJ
    Clin Interv Aging; 2006; 1(4):451-66. PubMed ID: 18046922
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [The treatment of the rubeosis of the iris and the neovascular glaucoma in proliferative diabetic retinopathy by means of anti-VEGF].
    Cernák M; Markovic O; Cernák A
    Cesk Slov Oftalmol; 2008 Nov; 64(6):234-6. PubMed ID: 19110964
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Neovascular age-related macular degeneration.
    Veritti D; Sarao V; Lanzetta P
    Ophthalmologica; 2012; 227 Suppl 1():11-20. PubMed ID: 22517121
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Targeting vascular endothelial growth factor: a promising strategy for treating age-related macular degeneration.
    Waisbourd M; Loewenstein A; Goldstein M; Leibovitch I
    Drugs Aging; 2007; 24(8):643-62. PubMed ID: 17702534
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Vascular endothelial growth factor inhibitors in the treatment of neovascular age-related macular degeneration].
    Dyakov IN; Zyryanov SK
    Vestn Oftalmol; 2017; 133(2):125-129. PubMed ID: 28524152
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Intraocular pressure in eyes receiving monthly ranibizumab in 2 pivotal age-related macular degeneration clinical trials.
    Bakri SJ; Moshfeghi DM; Francom S; Rundle AC; Reshef DS; Lee PP; Schaeffer C; Rubio RG; Lai P
    Ophthalmology; 2014 May; 121(5):1102-8. PubMed ID: 24393349
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Ranibizumab and aflibercept for the treatment of wet age-related macular degeneration.
    Yazdi MH; Faramarzi MA; Nikfar S; Falavarjani KG; Abdollahi M
    Expert Opin Biol Ther; 2015; 15(9):1349-58. PubMed ID: 26076760
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration.
    Lazic R; Gabric N
    Graefes Arch Clin Exp Ophthalmol; 2007 Jan; 245(1):68-73. PubMed ID: 17111146
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration.
    ; Apte RS; Modi M; Masonson H; Patel M; Whitfield L; Adamis AP
    Ophthalmology; 2007 Sep; 114(9):1702-12. PubMed ID: 17509689
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Safety and Efficacy of Anti-Vascular Endothelial Growth Factor Therapies for Neovascular Age-Related Macular Degeneration: A Report by the American Academy of Ophthalmology.
    Bakri SJ; Thorne JE; Ho AC; Ehlers JP; Schoenberger SD; Yeh S; Kim SJ
    Ophthalmology; 2019 Jan; 126(1):55-63. PubMed ID: 30077616
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Aflibercept for the treatment of neovascular age-related macular degeneration.
    Verner-Cole EA; Davis SJ; Lauer AK
    Drugs Today (Barc); 2012 May; 48(5):317-29. PubMed ID: 22645720
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: a report by the American Academy of Ophthalmology.
    Ip MS; Scott IU; Brown GC; Brown MM; Ho AC; Huang SS; Recchia FM;
    Ophthalmology; 2008 Oct; 115(10):1837-46. PubMed ID: 18929163
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES).
    Wu L; Martínez-Castellanos MA; Quiroz-Mercado H; Arevalo JF; Berrocal MH; Farah ME; Maia M; Roca JA; Rodriguez FJ;
    Graefes Arch Clin Exp Ophthalmol; 2008 Jan; 246(1):81-7. PubMed ID: 17674014
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.